» Articles » PMID: 25861374

Mutations in the PCNA-binding Site of CDKN1C Inhibit Cell Proliferation by Impairing the Entry into S Phase

Overview
Journal Cell Div
Publisher Biomed Central
Date 2015 Apr 11
PMID 25861374
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

CDKN1C (also known as P57 (kip2) ) is a cyclin-dependent kinase inhibitor that functions as a negative regulator of cell proliferation through G1 phase cell cycle arrest. Recently, our group described gain-of-function mutations in the PCNA-binding site of CDKN1C that result in an undergrowth syndrome called IMAGe Syndrome (Intrauterine Growth Restriction, Metaphyseal dysplasia, Adrenal hypoplasia, and Genital anomalies), with life-threatening consequences. Loss-of-function mutations in CDKN1C have been identified in 5-10% of individuals with Beckwith-Wiedemann syndrome (BWS), an overgrowth disorder with features that are the opposite of IMAGe syndrome. Here, we investigate the effects of IMAGe-associated mutations on protein stability, cell cycle progression and cell proliferation. Mutations in the PCNA-binding site of CDKN1C significantly increase CDKN1C protein stability and prevent cell cycle progression into the S phase. Overexpression of either wild-type or BWS-mutant CDKN1C inhibited cell proliferation. However, the IMAGe-mutant CDKN1C protein decreased cell growth significantly more than both the wild-type or BWS protein. These findings bring new insights into the molecular events underlying IMAGe syndrome.

Citing Articles

Phospholipid Scramblase 1 (PLSCR1) Regulates Interferon-Lambda Receptor 1 (IFN-λR1) and IFN-λ Signaling in Influenza A Virus (IAV) Infection.

Yang A, Ramos-Rodriguez L, Sorkhdini P, Yang D, Norbrun C, Majid S bioRxiv. 2024; .

PMID: 39605457 PMC: 11601549. DOI: 10.1101/2024.11.20.624469.


p57 Phosphorylation Modulates Its Localization, Stability, and Interactions.

Stampone E, Bencivenga D, Dassi L, Sarnelli S, Campagnolo L, Lacconi V Int J Mol Sci. 2024; 25(20).

PMID: 39456957 PMC: 11508627. DOI: 10.3390/ijms252011176.


Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells.

Ozgun G, Yaras T, Akman B, Ozden-Yilmaz G, Landman N, Karakulah G Cancer Gene Ther. 2024; 31(4):537-551.

PMID: 38233533 DOI: 10.1038/s41417-024-00725-3.


Structure-Function Analysis of p57KIP2 in the Human Pancreatic Beta Cell Reveals a Bipartite Nuclear Localization Signal.

Choleva L, Wang P, Liu H, Wood O, Lambertini L, Scott D Endocrinology. 2023; 165(2).

PMID: 38151968 PMC: 11491829. DOI: 10.1210/endocr/bqad197.


gene mutation causing familial Silver-Russell syndrome: A case report and review of literature.

Li J, Chen L, He H World J Clin Cases. 2023; 11(19):4655-4663.

PMID: 37469742 PMC: 10353515. DOI: 10.12998/wjcc.v11.i19.4655.


References
1.
Kato F, Hamajima T, Hasegawa T, Amano N, Horikawa R, Nishimura G . IMAGe syndrome: clinical and genetic implications based on investigations in three Japanese patients. Clin Endocrinol (Oxf). 2013; 80(5):706-13. DOI: 10.1111/cen.12379. View

2.
Watanabe H, Pan Z, Schreiber-Agus N, DePinho R, Hurwitz J, Xiong Y . Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A. 1998; 95(4):1392-7. PMC: 19016. DOI: 10.1073/pnas.95.4.1392. View

3.
Girard F, Strausfeld U, Fernandez A, Lamb N . Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991; 67(6):1169-79. DOI: 10.1016/0092-8674(91)90293-8. View

4.
Arboleda V, Lee H, Parnaik R, Fleming A, Banerjee A, Ferraz-de-Souza B . Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat Genet. 2012; 44(7):788-92. PMC: 3386373. DOI: 10.1038/ng.2275. View

5.
Chen B, Zhao R, Su C, Linan M, Tseng C, Phan L . CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle. 2012; 11(24):4633-41. PMC: 3562308. DOI: 10.4161/cc.22887. View